Baxter International Inc. (NYSE:BAX), a global leader in injectables, anesthesia and drug compounding, today announced five ...

intravenous for very severe or life-threatening disease Cyclophosphamide in severe disease; intravenous globulin, plasma exchange, rituximab in life-threatening situations but based on limited ...

The ACR has released a summary of a new 2024 guideline for the screening, treatment, and management of Lupus Nephritis.

SAN DIEGO -- A fixed-duration oral combination significantly reduced the risk of disease progression or death compared with ...

Developments in chronic lymphocytic leukemia (CLL) this year included the first CAR T-cell therapy approval for the chronic ...

Patients treated with Polivy in combination with R-CHP required fewer subsequent treatments, potentially reducing burdens on patients and healthcare systems1 These encouraging five-year results ...

Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda ...

Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV ...

Chemotherapy often causes hair loss, but it can depend on the type of chemo drug and other factors. An estimated 65% of people undergoing classic chemotherapy experience hair loss, or what doctors ...

A fever higher than 100.4 F following an injection warrants immediate medical care. Fevers this high may be due to an infection caused by needle contamination. Fever with chills is especially ...

Genmab (GMAB) announced new long-term results from two ongoing clinical trials evaluating epcoritamab, a T-cell engaging bispecific antibody ...